AMGN: TEZSPIRE4 FDA Approval; MariTide & Repatha

Published: November 4, 2025

AMGEN INC

Direct News

FDA approves TEZSPIRE4 (Amgen/AstraZeneca collaboration product) — announced 2025-11-04.
MariTide (maridebart cafraglutide) progresses to Phase 3 with six studies initiated in 2025 after positive Phase 2b 52-week results (Nov 2024).
Repatha shows Phase 3 progress and received a label expansion in August 2025 for broader LDL-C use.
FY2025 context: Total product sales $35,148M (up 10% YoY); U.S. accounts for $25,656M (73%).
Key structural risks remain: patent expirations (e.g., Prolia/XGEVA U.S. Feb 2025; select Europe Nov 2025), biosimilar pressure, and ongoing litigation.

Historical Context

TEZSPIRE4's approval in November 2025 follows a year in which Amgen prioritized label expansions and late‑stage development: in 2025 the company reported multiple label expansions and Phase 3 data across marketed franchises. MariTide's Phase 3 program in 2025 builds on a positive Phase 2b 52-week result from November 2024. Repatha's August 2025 label expansion and Phase 3 reporting are part of a longer-term lifecycle strategy to drive volume even as some older biologics face biosimilar competition. This event should be read against Amgen's FY2025 performance—10% product sales growth and a heavy U.S. revenue mix—and the documented structural risks (patent expirations, biosimilars, and legal proceedings) that the company cites in its filings. The TEZSPIRE4 approval is a constructive development for Amgen's near-term commercial profile, but its ultimate impact depends on uptake, reimbursement, and the company's ability to convert pipeline advances into sustainable revenue growth.

What the TEZSPIRE4 approval means for investors

The FDA approval of TEZSPIRE4 is a discrete regulatory win that strengthens Amgen's marketed portfolio and supports near-term revenue optionality in immunology. TEZSPIRE already sits within Amgen's broader collaboration framework (AstraZeneca noted in company filings), and an incremental approved indication or formulation (TEZSPIRE4) can contribute to volume growth through existing commercial channels. Investors should view this approval in the context of Amgen's FY2025 revenue mix: product sales reached $35.1 billion, with the U.S. representing roughly 73% of those sales. While TEZSPIRE4 provides revenue upside, the company still faces offsetting pressures from biosimilars and patent expirations on legacy biologics. The approval therefore reduces execution risk on commercialization for this asset but does not eliminate structural revenue exposures across the portfolio.

Pipeline momentum: MariTide and Repatha

MariTide's move into six Phase 3 trials in 2025 follows a positive Phase 2b 52-week readout in November 2024. As a GLP-1/GIPR peptide-antibody conjugate, MariTide represents a strategic R&D priority for Amgen and could materially affect growth if pivotal trials confirm efficacy and safety. Repatha's 2025 progress—combining Phase 3 activity and an August 2025 label expansion for broader LDL-C use—reinforces the commercial lifecycle strategy of label extensions to offset maturity in other franchises. Together, these pipeline updates illustrate Amgen's dual approach: defend revenue with label-expansion candidates like Repatha while pursuing higher-growth novel assets such as MariTide.

Balance of opportunity and risk

Amgen's competitive advantages remain patent protection, manufacturing scale, and physician switching barriers for biologics. However, filings highlight finite patent durations and concentrated litigation exposures. Notably, Prolia/XGEVA patent timelines (U.S. Feb 2025; select Europe Nov 2025) and biosimilar entrants are cited as key risks that can depress pricing and volumes. Management's stated strategic levers for the next three years include pipeline advancement, manufacturing expansion (Ohio, North Carolina, Puerto Rico sites), and capital allocation focused on dividends and repurchases. For investors, the TEZSPIRE4 approval and pipeline progress should be weighed against the company's need to replace lost exclusivity on legacy products and navigate ongoing legal and regulatory headwinds.

Investor FAQ

The most effective approach is to maintain a factual perspective. Keep a close watch on further developments at AMGEN INC as they unfold. Use primary source data to validate your investment thesis rather than relying on delayed secondary reports.

You can set up an automated tracker on Portrak. Our system monitors official SEC filings in real-time, delivering the most critical insights to your phone or inbox seconds after publication—frequently before the information reaches major financial news platforms.

We believe quality intelligence should be accessible. Our business model is supported by professional investors with large, complex portfolios who utilize Portrak Pro. These users pay to automate the monitoring of extensive watchlists, saving hundreds of hours in research time, which allows us to keep the standard service free for individual investors tracking their core positions.

Setting up your automated intelligence pipeline is a simple 3-step process:

Create Your Free Account

Select Your Focus

Use the search bar to find companies like AMGEN INC. Choose between monitoring specific events or receiving general market-moving intelligence. Our AI automatically determines what’s critical based on real-time market data and the company’s current profile.

Receive Real-Time Intelligence

Once activated, all official filings are analyzed instantly. Insights are delivered directly to your email or as a push notification if you use the Portrak mobile app.

Also available as a mobile app for iOS & Android—search for "Portrak"

More Strategic Insights

AMGN

Feb 19, 2026

Direct News

Historical Context

What the TEZSPIRE4 approval means for investors

Pipeline momentum: MariTide and Repatha

Balance of opportunity and risk

Investor FAQ

More Strategic Insights

Amgen Issues $4B Senior Notes Maturing to 2056

Amgen Reports Restructuring Charges, Intangible Impairments

Amgen Raises Q3 2025 Dividend 6% to $2.38

Amgen Q3 2025: Revenue +12%, EPS +14%